Visceral leishmaniasis mocrobiology
visceral leishmaniasis Leishmania donovani amastigote macrophage
This pathophysiology diagram illustrates the immunoregulatory role of IL-10-producing natural killer (NK) cells during Visceral Leishmaniasis caused by Leishmania donovani infection in a murine model. The timeline tracks disease progression at 7, 14, and 28 days post-infection. At 7 days, IL-10 production begins in the spleen. By 14 days, the diagram shows a central representation of the liver and spleen where splenic NK cells migrate into liver granulomas, becoming a primary source of the immunosuppressive cytokine IL-10. Visual details include hepatic granulomas depicted as clusters of cells within the liver parenchyma. At 28 days, the model demonstrates an adoptive transfer experiment where IL-10-producing NK cells are transferred into 21-day infected recipient mice, resulting in an increased parasite burden in both the liver and spleen. The diagram concludes that these cells inhibit host protective immunity against L. donovani, shifting the immune response from pro-inflammatory to immunosuppressive during the late stages of infection.
Two-panel clinical photograph (Figures 1A and 1B) illustrating atypical genital manifestations of visceral leishmaniasis in a patient with HIV coinfection. Panel A displays significant edema and swelling of the penile shaft. Panel B shows massive, diffuse scrotal swelling with a coarsely textured, thickened, and wrinkled skin surface. A focal nodular lesion is visible at the base of the scrotum. The visual findings represent cutaneous involvement in the context of systemic parasitic infection and immunodeficiency. This image serves as an educational reference for recognizing atypical extra-visceral presentations of Leishmania donovani infection, which may mimic other tropical or sexually transmitted diseases such as lymphogranuloma venereum. The presentation highlights the clinical significance of dermatological examination in HIV-positive patients living in or traveling from endemic regions (e.g., Ethiopia).
This figure presents genetic sequencing data analysis for maxicircle DNA (mitochondrial genome) coverage across 151 Leishmania isolates, supporting research into human visceral leishmaniasis. Panel A is a comparison chart featuring multiple boxplots. Each plot represents a specific sample (x-axis), showing the median, quartiles, and range of sequencing coverage (y-axis). This visualization highlights the significant variability in maxicircle DNA abundance and mapping success across different clinical isolates. Panel B is a line graph showing the minimum sequencing coverage across 116 high-coverage samples as a function of the nucleotide position on the L. donovani LV9 maxicircle reference (x-axis). The black line illustrates a fluctuating coverage profile, indicating regions of high and low mapping confidence along the mitochondrial genome. Two vertical red lines delineate a specific high-confidence region (approximately between positions 1,000 and 17,000) selected for subsequent phylogenetic reconstruction. This educational material demonstrates methods for qualifying genomic data and identifying conserved regions for species-level evolutionary analysis in parasitology and infectious diseases.
This diagnostic micrograph displays a protein crystal of Leishmania donovani pteridine reductase 1 (LdPTR1), a key enzyme in the parasite's folate metabolism. The visual demonstrates a single, well-defined orthorhombic plate crystal with approximate dimensions of 0.1 x 0.1 x 0.03 mm. The crystal is translucent with a smooth, planar surface and sharp geometric edges, though slight chromatic aberration is visible at the margins due to light refraction. This specimen was grown using the sitting-drop vapor diffusion method in a solution containing cofactor NADP+ and the inhibitor methotrexate. Such crystals are essential in structural biology and pharmacology for X-ray diffraction studies to determine the 3D molecular structure of protein targets, which is a critical step in rational drug design against visceral leishmaniasis. The image highlights the morphological characteristics required for successful crystallographic data collection in biomedical research.
"visceral leishmaniasis"[MeSH Terms] AND diagnosis
Visceral Leishmaniasis (VL) - Microbiology
The Organism
| Species | Transmission | Key Endemic Areas |
|---|---|---|
| L. donovani | Anthroponotic (human-to-human) | Indian subcontinent, East Africa |
| L. infantum (L. chagasi in the New World) | Zoonotic (dog reservoir) | Mediterranean, Middle East, Central Asia, Americas |
- Harrison's Principles of Internal Medicine 22E, p.1825
Morphology & Life Cycle
1. Promastigote (extracellular, in sandfly)
- Elongated, flagellated form (10-15 µm)
- Lives in the gut of the female sandfly vector
- Infective stage - inoculated into the human host during a blood meal
2. Amastigote (intracellular, in human)
- Small, ovoid, non-flagellated (2-4 µm)
- Contains a nucleus and a characteristic kinetoplast (rod-like, contains multiple copies of mitochondrial DNA) - seen as a "dot" (nucleus) and "dash" (kinetoplast) on Giemsa stain
- Obligate intracellular parasite, residing within macrophages
Life Cycle Steps
- Female sandfly (Phlebotomus spp. in Old World; Lutzomyia spp. in New World) takes a blood meal and inoculates promastigotes
- Promastigotes are phagocytosed by macrophages/monocytes
- Inside the phagolysosome, promastigotes transform into amastigotes
- Amastigotes multiply by binary fission, fill the cell cytoplasm, and burst the cell
- Released amastigotes are phagocytosed by more macrophages - cycle repeats
- Parasite spreads via the reticuloendothelial system to spleen, liver, bone marrow, and lymph nodes
- Sandfly ingests amastigotes during feeding; amastigotes convert back to promastigotes in the sandfly gut
- Jawetz, Melnick & Adelberg's Medical Microbiology 28th Ed.
- Harrison's Principles of Internal Medicine 22E
Vectors
| Region | Vector |
|---|---|
| Indian subcontinent | Phlebotomus argentipes |
| East Africa (Sudan, Ethiopia) | P. orientalis, P. martini |
| Mediterranean/Middle East | P. perniciosus, P. ariasi |
| Americas | Lutzomyia longipalpis |
Epidemiology
-
East Africa now has the highest global incidence, followed by Brazil and the Indian subcontinent
-
WHO has declared elimination as a public health problem in Bangladesh and near-elimination in Nepal and India (98.7% decline)
-
In Mediterranean Europe, 70% of adult VL cases are HIV co-infected
-
IV drug users are at particular risk for co-infection
-
Children predominantly affected in immunocompetent endemic areas (Americas, Mediterranean); all ages affected in India and East Africa
-
Harrison's Principles of Internal Medicine 22E, p.1825
Immunopathogenesis
-
Protective response: IL-12 from antigen-presenting cells → IFN-γ, TNF-α from Th1 cells → activation of macrophages → nitric oxide production → parasitic killing
-
Disease promotion: Markedly elevated serum IL-10 in active VL
- IL-10 renders macrophages unresponsive to activation signals
- Downregulates TNF-α and nitric oxide production
- Suppresses antigen-presentation by DCs and macrophages
- Parasite survives and multiplies unopposed
-
Organs of the reticuloendothelial system (spleen, liver, lymph nodes, bone marrow) are predominantly affected
-
Polyclonal hypergammaglobulinemia occurs (antibodies are non-protective)
-
Patients with active disease have negative leishmanin skin tests (Montenegro test) - unlike immune individuals who show delayed-type hypersensitivity
-
Harrison's Principles of Internal Medicine 22E, p.1826
Clinical Features
- Incubation period: 2-3 months (up to 1 year)
- Fever: Intermittent, moderate-to-high grade with rigors/chills (classically biphasic - two daily spikes)
- Massive splenomegaly - hallmark finding (palpable by 2nd week, can be enormous)
- Hepatomegaly - usually moderate
- Lymphadenopathy - common everywhere except Indian subcontinent
- Weight loss, weakness
- Hyperpigmentation of skin (gives rise to the name kala-azar)
- Advanced disease: hypoalbuminemia → pedal edema and ascites
Labs
- Pancytopenia - leukopenia, anemia, thrombocytopenia (bone marrow involvement)
- Markedly elevated serum immunoglobulins (polyclonal)
- Raised hepatic aminotransferases
- Occasional hyperbilirubinemia
Diagnosis
Gold Standard
- Demonstration of amastigotes in tissue aspirate smears (Giemsa stain)
| Specimen | Sensitivity |
|---|---|
| Splenic aspirate | >95% (most sensitive but invasive) |
| Bone marrow aspirate | 60-85% |
| Lymph node aspirate | ~50% |
Serologic Tests
- ELISA and IFAT - used in sophisticated labs
- rK39 Rapid Diagnostic Test (RDT) - most widely used field test
- Detects antibodies to a recombinant antigen (39 amino acids from the kinesin region of L. infantum)
- Requires only a fingerprick drop of blood; result in 15 minutes
- Sensitivity ~98%, specificity ~90% in immunocompetent patients (lower in East Africa)
- Cannot be used to monitor cure or detect relapse (remains positive for years)
Molecular Tests
-
PCR - qualitative, highly sensitive, allows species identification
-
Real-time (quantitative) PCR - can monitor parasite load
-
LAMP (Loop-mediated isothermal amplification) - newer, performs better than microscopy using blood; simple visual readout, suitable for point-of-care in endemic areas
-
Harrison's Principles of Internal Medicine 22E, p.1827
Post-Kala-Azar Dermal Leishmaniasis (PKDL)
- A dermatosis that develops as a sequela after apparently successful treatment of VL
- Indian subcontinent variant: polymorphic lesions (macules, patches) coexisting with nodules
- Important reservoir of infection for maintaining anthroponotic transmission cycles
Treatment (Key Points)
- Liposomal amphotericin B - drug of choice in most settings (single-dose regimen in India)
- Miltefosine - oral agent; first-line in Indian subcontinent
- Antimonials (sodium stibogluconate, meglumine antimoniate) - historically first-line, now with widespread resistance in Bihar, India
- Amphotericin B deoxycholate - effective but toxic
- Paromomycin - aminoglycoside, used in combination regimens in East Africa
Summary Table
| Feature | Detail |
|---|---|
| Causative agents | L. donovani, L. infantum |
| Vector | Female sandfly (Phlebotomus / Lutzomyia) |
| Infective stage | Promastigote |
| Intracellular stage | Amastigote (in macrophages) |
| Key organelle | Kinetoplast (mitochondrial DNA) |
| Hallmark sign | Massive splenomegaly |
| Gold standard diagnosis | Splenic smear (>95% sensitivity) |
| Best field test | rK39 RDT |
| Immune evasion key | IL-10 - suppresses macrophage activation |
| Drug of choice | Liposomal amphotericin B / miltefosine |
Visceral leishmaniasis microbiology
Visceral Leishmaniasis (VL) - Microbiology
The Organism
| Species | Transmission | Key Endemic Areas |
|---|---|---|
| L. donovani | Anthroponotic (human-to-human) | Indian subcontinent, East Africa |
| L. infantum (L. chagasi in the New World) | Zoonotic (dog reservoir) | Mediterranean, Middle East, Central Asia, Americas |
Morphology & Life Cycle
1. Promastigote (in the sandfly - extracellular)
- Elongated, flagellated (10-15 µm)
- The infective stage - inoculated into the human host during a sandfly bite
2. Amastigote (in the human host - intracellular)
- Small, ovoid, non-flagellated (2-4 µm)
- Contains a nucleus and a distinctive kinetoplast (rod-like; packed mitochondrial DNA) - seen as a "dot and dash" on Giemsa stain
- Lives and multiplies inside macrophages
Life Cycle Steps
- Female sandfly inoculates promastigotes during a blood meal
- Promastigotes are phagocytosed by skin macrophages/monocytes
- Inside the phagolysosome, they transform into amastigotes
- Amastigotes multiply by binary fission, eventually burst the cell
- Released amastigotes are phagocytosed by more macrophages - cycle repeats
- Parasite disseminates via the reticuloendothelial system to spleen, liver, bone marrow, lymph nodes
- A new sandfly ingests amastigotes during feeding; these revert to promastigotes in the sandfly midgut
Vectors
| Region | Sandfly Vector |
|---|---|
| Indian subcontinent | Phlebotomus argentipes |
| East Africa | P. orientalis, P. martini |
| Mediterranean / Middle East | P. perniciosus, P. ariasi |
| Americas | Lutzomyia longipalpis |
Epidemiology
- East Africa carries the highest global burden, followed by Brazil and the Indian subcontinent
- WHO declared elimination as a public health problem in Bangladesh; India reported a 98.7% decline
- In Mediterranean Europe, 70% of adult VL cases are HIV co-infected
- L. infantum is the species in HIV/VL co-infection; IV drug users are a key at-risk group
- Reservoir for L. donovani: humans (anthroponotic); for L. infantum: dogs, foxes, jackals
Immunopathogenesis
- IL-12 (from APCs) → Th1 cells → IFN-γ + TNF-α → macrophage activation → nitric oxide → parasite killing
- These individuals test positive on the leishmanin (Montenegro) skin test (delayed-type hypersensitivity)
- Markedly elevated serum IL-10 suppresses macrophage activation
- IL-10 downregulates TNF-α and nitric oxide production
- Antigen-presentation by DCs and macrophages is suppressed
- Parasite survives and multiplies unchecked
- Polyclonal hypergammaglobulinemia develops (antibodies are non-protective)
- Patients have negative leishmanin skin tests during active disease
Clinical Features
- Incubation: 2-3 months (up to 1 year)
- Fever: Intermittent, moderate-to-high grade, with rigors/chills; classically biphasic (two daily spikes)
- Massive splenomegaly - the hallmark (palpable by week 2; can be enormous - see figure below)
- Moderate hepatomegaly
- Lymphadenopathy - present in most regions, rare on the Indian subcontinent
- Weight loss, weakness
- Skin hyperpigmentation - the origin of "kala-azar" (dark fever)
- Advanced: hypoalbuminemia → pedal edema, ascites
Laboratory Findings
| Finding | Cause |
|---|---|
| Pancytopenia (leukopenia, anemia, thrombocytopenia) | Bone marrow infiltration + hypersplenism |
| Polyclonal hypergammaglobulinemia | Non-specific B cell activation |
| Raised hepatic transaminases | Liver involvement |
| Hypoalbuminemia | Chronic disease |
Diagnosis
Gold Standard
| Specimen | Sensitivity |
|---|---|
| Splenic aspirate | >95% (most sensitive but invasive) |
| Bone marrow aspirate | 60-85% |
| Lymph node aspirate | ~50% |
Serologic Tests
- ELISA / IFAT - used in reference labs
- rK39 Rapid Diagnostic Test (RDT) - workhorse field test
- Detects antibodies to a recombinant antigen (39 amino acids from the kinesin region of L. infantum)
- Only a fingerprick of blood; result in 15 minutes
- Sensitivity ~98%, specificity ~90% in immunocompetent patients
- Sensitivity/specificity lower in East Africa
- Remains positive for years after cure - cannot be used to monitor treatment response
Molecular Diagnostics
- PCR - qualitative; highly sensitive; allows species identification
- Real-time PCR - quantitative; can monitor parasite load and relapse
- LAMP - performs better than microscopy on blood; minimal equipment needed; suitable for point-of-care use in endemic settings
Post-Kala-Azar Dermal Leishmaniasis (PKDL)
- Develops after apparently successful treatment of VL
- Indian subcontinent: polymorphic lesions (macules/patches + nodules)
- Important as a reservoir for continued anthroponotic transmission
Treatment Overview
| Drug | Notes |
|---|---|
| Liposomal amphotericin B | Drug of choice globally; single-dose regimen used in India |
| Miltefosine | Oral agent; first-line in Indian subcontinent |
| Sodium stibogluconate / Meglumine antimoniate | Historic first-line; widespread resistance in Bihar, India |
| Paromomycin | Aminoglycoside; used in combination in East Africa |
| Amphotericin B deoxycholate | Effective but nephrotoxic |
Quick Summary Table
| Feature | Detail |
|---|---|
| Causative agents | L. donovani, L. infantum |
| Vector | Female sandfly (Phlebotomus / Lutzomyia) |
| Infective stage (to human) | Promastigote |
| Intracellular stage | Amastigote (in macrophages) |
| Diagnostic organelle | Kinetoplast ("dot and dash") |
| Hallmark clinical sign | Massive splenomegaly |
| Gold standard diagnosis | Splenic smear (>95%) |
| Best field test | rK39 RDT (15 min, fingerprick) |
| Key immune evasion mechanism | IL-10 suppresses macrophage activation |
| Drug of choice | Liposomal amphotericin B / miltefosine |
Lymphatic filariasis
lymphatic filariasis elephantiasis microfilaria Wuchereria bancrofti
Two-panel clinical photograph illustrating the manifestations of lymphatic filariasis (elephantiasis) caused by Wuchereria bancrofti. Image A displays a side profile of the left lower limb exhibiting severe, generalized lymphedema from the foot to the groin. There is significant swelling and skin folds, erythematous patches on the thigh, and trophic skin changes including perimaleolar hypocromia and hypercromia. Image B provides a frontal view of the pelvic region, showing massive, bulbous scrotal edema (hydrocele) and induration. The skin of the scrotum appears thickened and tense. These findings are characteristic of chronic lymphatic obstruction leading to massive tissue enlargement and secondary dermatological changes. The images are highly relevant for tropical medicine and infectious disease specialties, demonstrating the late-stage physical sequelae of nematode-induced lymphatic damage.
This set of clinical photographs illustrates chronic manifestations of lymphatic filariasis, a parasitic disease caused by Wuchereria bancrofti. Image (a) shows bilateral lymphedema of the lower extremities, characterized by significant swelling (elephantiasis) extending from the feet to the lower legs, with visible skin thickening, hyperkeratosis, and textural changes. Image (b) demonstrates unilateral lymphedema, where the right lower extremity exhibits marked enlargement and swelling compared to the relatively normal left leg. Image (c) displays severe scrotal swelling, indicative of a large hydrocele. The scrotal sac is massively distended, obscuring normal genital contours due to lymphatic fluid accumulation. These images highlight the progressive morbidity and physical deformities associated with untreated chronic lymphatic obstruction in endemic regions. The visuals serve as educational markers for late-stage morbidity management and disability prevention (MMDP) in tropical medicine.
Educational multi-panel figure illustrating the clinical and pathological findings of lymphatic filariasis (Wuchereria bancrofti) masquerading as vasculitis. Panel A (Clinical Photograph): Displays the lower extremities of a patient with dry gangrene of the right hallux and lesser digits, alongside an ulcerated nodule on the left shin and diffuse skin excoriation, indicating severe peripheral vascular compromise. Panel B (Peripheral Blood Film): Giemsa-stained blood smear showing a characteristic microfilaria (approximately 240-250 um long) with identifiable micromorphological features. Panels C and D (Histopathology): Haematoxylin and Eosin (H&E) stained skin biopsy sections from the shin nodule. Low-power magnification (C, 100x) reveals dense inflammatory infiltrates spanning the dermis and subcutaneous fat with capillary proliferation. High-power magnification (D, 1000x) demonstrates a microfilaria (arrow) localized within a capillary lumen, surrounded by a mixed inflammatory cell population consisting of plasma cells, lymphocytes, and neutrophils. This visual set demonstrates the importance of parasitic evaluation in cases of atypical limb ischemia and nodular skin lesions.
A clinical photograph depicting four male patients seated in a row, participating in foot hygiene practices for the management of lymphatic filariasis. The patients are seated in plastic chairs, each with their lower limbs positioned in basins containing soapy water. The individual on the far right exhibits advanced elephantiasis of the right lower extremity, characterized by massive non-pitting lymphedema, significant limb distortion, and skin thickening (pachydermia) with visible skin folds. Other patients show varying degrees of lower limb involvement or are engaged in preventive hygiene. The scene illustrates morbidity management and disability prevention (MMDP) protocols, specifically focusing on local skin care and hygiene to prevent secondary bacterial infections (dermatolymphangioadenitis) in patients with neglected tropical diseases (NTDs). The setting appears to be a community-based health intervention in a region endemic for Wuchereria bancrofti or Brugia malayi.
"lymphatic filariasis"[MeSH Terms] AND treatment
Lymphatic Filariasis
The Organisms
| Species | Proportion of cases | Key Endemic Areas |
|---|---|---|
| Wuchereria bancrofti | ~90% of all cases | Tropics/subtropics worldwide - Africa, South Asia, Southeast Asia, Pacific Islands, Americas |
| Brugia malayi | Most remaining cases | Eastern India, Indonesia, Malaysia, Philippines |
| Brugia timori | Minor | Islands of southeastern Indonesia only |
- Robbins & Cotran Pathologic Basis of Disease; Harrison's Internal Medicine 22E, p.1863
Morphology
Adult Worms
- Long, threadlike (males ~4 cm; females ~8-10 cm)
- Live in afferent lymphatics and lymph node sinuses
- May remain viable for >20 years
- W. bancrofti adults found in cross-section within lymphatics: associated lymphatic fibrosis (see panel E below)
Microfilariae (larval stage circulating in blood)
- Elongated larvae, ~220-300 µm
- Sheathed in all three lymphatic filarial species (the sheath is the remnant of the egg membrane)
- Key distinguishing features on Giemsa stain:
- W. bancrofti: tail tip has no nuclei; sheath does not readily stain with Giemsa
- B. malayi: two discrete nuclei at the tail tip; sheath stains deep pink with Giemsa
- Loa loa (for comparison): nuclei extending to the tail tip; diurnal periodicity
Life Cycle
- Infected mosquito takes a blood meal and deposits infective L3 larvae (filariform larvae) onto the skin; larvae enter through the bite wound
- L3 larvae migrate to lymphatic vessels and lymph nodes, where they develop through L4 into adult worms over 6-12 months
- Mated female adult worms release microfilariae into the bloodstream
- Microfilariae circulate in peripheral blood with nocturnal periodicity (peak at night, coinciding with mosquito feeding hours)
- A mosquito ingests microfilariae during a blood meal; microfilariae develop into infective L3 larvae in the mosquito's flight muscles over ~10-14 days
- Cycle repeats with the next bite
Vectors
| Region | Principal Mosquito Vector |
|---|---|
| Urban settings globally | Culex spp. (esp. C. quinquefasciatus) |
| Rural settings | Anopheles or Aedes spp. |
| B. malayi (nocturnal form) | Mansonia, Anopheles spp. |
| Pacific Islands (subperiodic W. bancrofti) | Aedes spp. |
Subperiodic forms: In the Pacific Islands (W. bancrofti) and forested areas (B. malayi), microfilariae circulate at all times, peaking in the afternoon - matching daytime biting vectors.
Epidemiology
- ~51 million people affected by W. bancrofti worldwide; total LF burden ~50-70 million
- Humans are the only definitive host for W. bancrofti
- B. malayi naturally also infects cats (zoonotic reservoir)
- A WHO-led global program for elimination (GPELF) using mass drug administration has significantly reduced case numbers
- Still endemic across 49 countries in Africa, Asia, Western Pacific, and the Americas
Pathogenesis & Immunology
Parasite Immune Evasion
- Elastases and trypsin-like proteases - facilitate tissue invasion
- Surface glycoproteins with antioxidant function - protect against reactive oxygen species
- Cystatin homologues - impair MHC class II antigen processing
- Serpins - inhibit neutrophil proteases (key inflammatory mediators)
- TGF-β and macrophage migration inhibitory factor homologues - dampen the host immune response
Role of Wolbachia
- Filarial nematodes harbor intracellular Wolbachia bacteria (endosymbionts)
- Wolbachia is required for nematode development and reproduction
- Antibiotics targeting Wolbachia (e.g., doxycycline) impair nematode survival and fertility
- Released Wolbachia antigens may contribute to inflammatory pathology
- Side effects of DEC/ivermectin treatment (fever, chills) may partly result from Wolbachia released from dying parasites
Pathology of Lymphatics
-
Adult worms (not microfilariae) cause the principal pathological damage
-
Adults cause lymphatic dilation, thickening of vessel walls, and infiltration of plasma cells, eosinophils, and macrophages
-
Repeated episodes lead to lymphangitis and lymphadenitis
-
Chronic infection results in fibrosis and obstruction of lymphatic vessels
-
Result: lymphedema and ultimately elephantiasis
-
Robbins & Cotran Pathologic Basis of Disease; Harrison's Internal Medicine 22E, p.1863
Clinical Stages
Stage 1: Asymptomatic Amicrofilaremia
- Exposed individual with no detectable microfilariae and no symptoms
- May reflect resistance to infection or undetectable infection level
Stage 2: Asymptomatic Microfilaremia
- Blood positive for microfilariae but no clinical disease
- Important reservoir in the community
- Subclinical lymphatic damage often present (hematuria, proteinuria on testing)
- Detected by night blood examination
Stage 3: Acute Manifestations
- Recurrent episodes of acute adenolymphangitis (ADL):
- Filarial fever
- Retrograde lymphangitis (travels from lymph node distally - distinguishes from bacterial ascending lymphangitis)
- Lymphadenitis
- Lymphedema of affected region
- Epididymo-orchitis in males
Stage 4: Chronic Obstructive Lesions (develops 10-15 years after first acute episode)
| Manifestation | Description |
|---|---|
| Elephantiasis | Massive, non-pitting lymphedema; most commonly legs, then scrotum, arms, penis, vulva, breasts |
| Hydrocele | Scrotal fluid accumulation (most common chronic manifestation of Bancroftian filariasis) |
| Chyluria | Milky urine due to leakage of chyle into the urinary tract |
| Tropical pulmonary eosinophilia (TPE) | Occult filariasis - hypersensitivity to microfilarial antigens; eosinophilia, nocturnal cough/wheezing, high IgE |
Brugian filariasis is generally milder than Bancroftian and rarely involves the genitalia (unless co-existing with Bancroftian infection).
Diagnosis
Direct Detection
| Method | Notes |
|---|---|
| Thick blood smear (Giemsa/Field stain) | Collected at night (10 PM - 2 AM) to match nocturnal periodicity; gold standard for microfilariae |
| Concentration techniques (membrane filtration, Knott's method) | More sensitive when microfilariae are sparse |
| Histopathology | Adult worms in cross-section within lymphatics |
Antigen Detection
- Circulating Filarial Antigen (CFA) ELISA or immunochromatographic card test - detects W. bancrofti adult worm antigen; highly sensitive and specific; can be performed during the day (no periodicity issue)
Antibody Tests
- ELISA/IFAT - less specific due to cross-reactivity with other helminths
Imaging
- Ultrasound ("filarial dance sign") - real-time movement of live adult worms in dilated scrotal lymphatics is pathognomonic
- Lymphoscintigraphy - reveals subclinical lymphatic dysfunction even in asymptomatic individuals
Molecular
- PCR - highly sensitive; used for species identification and epidemiological surveys
Treatment
Active Infection
| Drug | Dose / Regimen | Action |
|---|---|---|
| DEC (diethylcarbamazine) | 6 mg/kg/day × 12 days | Macro- and microfilaricidal; drug of choice |
| Albendazole | 400 mg twice daily × 21 days | Macrofilaricidal |
| Doxycycline | 4-6 week course (targets Wolbachia) | Significant macrofilaricidal activity; improves lymphedema |
| Ivermectin | 200 µg/kg single dose | Microfilaricidal (used in Africa where DEC contraindicated due to co-endemic Loa loa) |
Mass Drug Administration (MDA) Regimens
- Albendazole + DEC (single annual doses) - regions without Loa loa co-endemicity
- Albendazole + Ivermectin - Africa (DEC avoided due to Loa loa risk)
- Triple therapy (Albendazole + DEC + Ivermectin) - single-dose regimen shown to sustain microfilarial clearance for ≥2 years; accelerates elimination programs
Caution: In Loa loa co-endemic areas, both DEC and ivermectin can precipitate severe encephalopathy in patients with high Loa loa microfilaremia.
Chronic Manifestations
- Lymphedema management: skin hygiene, limb elevation, exercise (complex decongestive physiotherapy), prevention of secondary bacterial infections
- Hydrocele: surgical correction
- Doxycycline (6 weeks) can improve filarial lymphedema even without confirmed active infection
- DEC has no benefit for irreversible elephantiasis
Side Effects of DEC/Ivermectin
-
Fever, chills, arthralgias, headache, nausea, vomiting
-
Severity proportional to microfilarial load
-
Mediated by antigens/Wolbachia released from dying parasites (Mazzotti-like reaction)
-
Harrison's Internal Medicine 22E, p.1865
Summary Table
| Feature | W. bancrofti | B. malayi | B. timori |
|---|---|---|---|
| Global burden | ~90% | Most remainder | Minor |
| Distribution | Worldwide tropics | East/SE Asia | SE Indonesia only |
| Vector | Culex, Anopheles, Aedes | Mansonia, Anopheles | Anopheles |
| Periodicity | Nocturnal (subperiodic in Pacific) | Nocturnal / Subperiodic | Subperiodic |
| Microfilariae sheath | Present (weak Giemsa) | Present (deep pink Giemsa) | Present |
| Tail tip nuclei | Absent | 2 discrete nuclei | Present |
| Genital involvement | Common (hydrocele, scrotal elephantiasis) | Rare | Rare |
| Zoonotic reservoir | None (humans only) | Cats | None known |
| Drug of choice | DEC | DEC | DEC |
Quick Concept Map
Mosquito bite → L3 larvae → Lymphatics → Adult worms (20+ yr lifespan)
↓
Microfilariae → Bloodstream (nocturnal)
↓
Lymphatic inflammation + obstruction
↓
Acute: fever, lymphangitis, ADL → Chronic: elephantiasis, hydrocele, chyluria
↓
Occult: Tropical Pulmonary Eosinophilia